Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

ATG-037SelinexorPositive

AI Analysis

Summary

Antengene published preclinical research on CD73 small molecule inhibitor ATG-037 combined with selinexor for cancer treatment. The announcement is a routine research publication without clinical data or regulatory milestones.

Outcome Details

Preclinical research paper publication on CD73 small molecule inhibitor combined with selinexor

Importance:3/10

Sentiment:

0.30

preclinicalresearchCD73 inhibitorcombination therapycancergene therapy

Related Companies

$INTI $GBCYD $TRAX

Read the original article

Published by PR Newswire Clinical Trials on September 14, 2026 4:26 AM

Read Original